This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sodium/glucose cotransporter
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
== Function == | == Function == | ||
| - | '''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney<ref>PMID:26125647 | + | '''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney<ref>PMID:26125647</ref>. |
== Disease == | == Disease == | ||
| + | |||
| + | Mutations in SGLT1 cause malabsorption of glucose and galactose<ref>PMID:31081587</ref>. | ||
== Relevance == | == Relevance == | ||
Revision as of 07:41, 15 April 2024
| |||||||||||
References
- ↑ Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9. PMID:26125647 doi:10.1097/MNH.0000000000000152
- ↑ Dominguez Rieg JA, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):43-52. PMID:31081587 doi:10.1111/dom.13630
- ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939
